

- Siegel R, Naishadham D, Jemal A. Cancer Statistics, 2013. *CA Cancer J Clin* 2013;63:11–30.
- Cannistra SA. Cancer of the ovary. *N Engl J Med* 2004;351:2519–2529.
- Hankinson SE, Hunter DJ, Colditz GA, et al. Tubal ligation, hysterectomy, and risk of ovarian cancer. A prospective study. *JAMA* 1993;270:2813.
- Young RH. A brief history of the pathology of the gonads. *Mod Pathol* 2005;18:S3.
- Levanon K, Crum C, Drapkin R. New insights into the pathogenesis of serous ovarian cancer and its clinical impact. *J Clin Oncol* 2008;26:5284–5293.
- The Cancer Genome Atlas. Integrated genomic analyses of ovarian carcinoma. *Nature* 2011;474:609–615.
- Wiegand KC, Shah SP, Al-Agha OM, et al. ARID1A mutations in endometriosis-associated ovarian carcinomas. *N Engl J Med* 2010;363:1532–1543.
- Bookman MA, Darcy KM, Clarke-Pearson D, et al. Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group. *J Clin Oncol* 2003;21:283–290.
- Tai YT, Lee S, Niloff E, et al. BAX protein expression and clinical outcome in epithelial ovarian cancer. *J Clin Oncol* 1998;16:2583–2590 [erratum appears in *J Clin Oncol* 1998;16:3211].
- Cannistra SA, Ottensmeier C, Niloff J, et al. Expression and function of beta 1 and alpha v beta 3 integrins in ovarian cancer. *Gynecol Oncol* 1995;58:216–225.
- Alvarez AA, Krigman HR, Whitaker RS, et al. The prognostic significance of angiogenesis in epithelial ovarian carcinoma. *Clin Cancer Res* 1999;5:587–591.
- Leake JF, Currie JL, Rosenshein NB, et al. Long-term follow-up of serous ovarian tumors of low malignant potential. *Gynecol Oncol* 1992;47:150–158.
- Seidman JD, Ronnett BM, Kurman RJ. Pathology of borderline (low malignant potential) ovarian tumours. *Best Pract Res Clin Obstet Gynaecol* 2002;16:499–512.
- Omura GA, Brady MF, Homesley HD, et al. Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience. *J Clin Oncol* 1991;9:1138–1150.
- Gershenson DM, Sun CC, Lu KH, et al. Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary. *Obstet Gynecol* 2006;108:361–368.
- Gershenson DM, Sun CC, Bodurka D, et al. Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant. *Gynecol Oncol* 2009;114:48–52.
- Soliman PT, Slomovitz BM, Broaddus RR, et al. Synchronous primary cancers of the endometrium and ovary: a single institution review of 84 cases. *Gynecol Oncol* 2004;94:456–462.
- Bast RC Jr, Knapp RC. Use of the CA 125 antigen in diagnosis and monitoring of ovarian carcinoma. *Euro J Obstet Gynecol Reprod Biol* 1985;19:354–356.
- Rustin CJ, Van Der Burg ME. A randomized trial in ovarian cancer (OC) of early treatment of relapse based on CA125 level alone versus delayed treatment based on conventional clinical indicators (MRC OV05/EORTC 55955 trials). *Proc Am Soc Clin Oncol* 2009;27:Abstr 1.
- Karlan BY. The status of ultrasound and color Doppler imaging for the early detection of ovarian carcinoma. *Cancer Invest* 1997;15:265–269.
- Modesitt SC, Pavlik EJ, Ueland FR, et al. Risk of malignancy in unilocular ovarian cystic tumors less than 10 centimeters in diameter. *Obstet Gynecol* 2003;102:594–599.
- Chen DX, Schwartz PE, Li XG, et al. Evaluation of CA 125 levels in differentiating malignant from benign tumors in patients with pelvic masses. *Obstet Gynecol* 1988;72:23–27.
- Markman M. The use of PET scanning in ovarian cancer. *Gynecol Oncol* 2002;85:391; author reply 391–392.
- Jacobs I. Genetic, biochemical, and multimodal approaches to screening for ovarian cancer. *Gynecol Oncol* 1994;55:S22–S27.
- van Haaften-Day C, Shen Y, Xu F, et al. OVX1, macrophage-colony stimulating factor, and CA-125-II as tumor markers for epithelial ovarian carcinoma: a critical appraisal. *Cancer* 2001;92:2837–2844.
- Xu Y, Shen Z, Wiper DW, et al. Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers. *JAMA* 1998;280:719–723.
- National Institutes of Health Consensus Development Conference Statement. Ovarian cancer: screening, treatment, and follow-up. *Gynecol Oncol* 1994;55:S4–S14.
- van Nagell JR Jr, DePriest PD, Reedy MB, et al. The efficacy of transvaginal sonographic screening in asymptomatic women at risk for ovarian cancer. *Gynecol Oncol* 2000;77:350–356.
- Kramer BS, Gohagan J, Prorok PC, et al. A National Cancer Institute sponsored screening trial for prostatic, lung, colorectal, and ovarian cancers. *Cancer* 1993;71:589–593.
- Buyss SS, Partridge E, Black A, et al. Effect of screening on ovarian cancer mortality: the prostate, lung, colorectal and ovarian (plco) cancer screening randomized controlled trial. *JAMA* 2011;305:2295–2303.
- Jacobs IJ, Skates SJ, MacDonald N, et al. Screening for ovarian cancer: a pilot randomised controlled trial. *Lancet* 1999;353:1207–1210.
- Skates SJ, Xu FJ, Yu YH, et al. Toward an optimal algorithm for ovarian cancer screening with longitudinal tumor markers. *Cancer* 1995;76:2004–2010.
- Ford D, Easton DF, Bishop DT, et al. Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. *Lancet* 1994;343:692–695.
- Tavtigian SV, Simard J, Rommens J, et al. The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds. *Nat Genet* 1996;12:333–337.
- Levine DA, Argenta PA, Yee CJ, et al. Fallopian tube and primary peritoneal carcinomas associated with BRCA mutations. *J Clin Oncol* 2003;21:4222–4227.
- Boyd J, Rubin SC. Hereditary ovarian cancer: molecular genetics and clinical implications. *Gynecol Oncol* 1997;64:196–206.
- Tonin P, Weber B, Offit K, et al. Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families. *Nat Med* 1996;2:1179–1183.
- Struwing JP, Hartge P, Wacholder S, et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. *N Engl J Med* 1997;336:1401–1408.
- Rubin SC, Benjamin I, Behbakht K, et al. Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1 [see comment]. *N Engl J Med* 1996;335:1413–1416.
- Frank TS, Deffenbaugh AM, Reid JE, et al. Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. *J Clin Oncol* 2002;20:1480–1490.
- Cass I, Baldwin RL, Varkey T, et al. Improved survival in women with BRCA-associated ovarian carcinoma. *Cancer* 2003;97:2187–2195.
- Watson P, Butzow R, Lynch HT, et al. The clinical features of ovarian cancer in hereditary nonpolyposis colorectal cancer. *Gynecol Oncol* 2001;82:223–228.
- Bonadona V, Bonaiti B, Olschwang S, et al. Cancer risks associated with germline mutations in mlh1, msh2, and msh6 genes in lynch syndrome. *JAMA* 2011;305:2304–2310.
- American Society of Clinical Oncology. American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility. *J Clin Oncol* 2003;21:2397–2406.
- Walsh T, Casadei S, Coats KH, et al. Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. *JAMA* 2006;295:1379–1388.
- Rebbeck TR, Lynch HT, Neuhausen SL, et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. *N Engl J Med* 2002;346:1616–1622.
- Kauff ND, Satagopan JM, Robson ME, et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. *N Engl J Med* 2002;346:1609–1615.
- Domchek SM, Friebel TM, Singer CF, et al. Association of risk-reducing surgery in brca1 or brca2 mutation carriers with cancer risk and mortality. *JAMA* 2010;304:967–975.
- Burke W, Daly M, Garber J, et al. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium. *JAMA* 1997;277:997–1003.
- Paley PJ, Swisher EM, Garcia RL, et al. Occult cancer of the fallopian tube in BRCA-1 germline mutation carriers at prophylactic oophorectomy: a case for recommending hysterectomy at surgical prophylaxis [see comment]. *Gynecol Oncol* 2001;80:176–180.
- Lu KH, Garber JE, Cramer DW, et al. Occult ovarian tumors in women with BRCA1 or BRCA2 mutations undergoing prophylactic oophorectomy. *J Clin Oncol* 2000;18:2728–2732.
- Garber JE, Hartman AR. Prophylactic oophorectomy and hormone replacement therapy: protection at what price? *J Clin Oncol* 2004;22:978–980.
- Narod SA, Dube MP, Klijn J, et al. Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. *J Natl Cancer Inst* 2002;94:1773–1779.
- Holtz F, Hart WR. Krukenberg tumors of the ovary: a clinicopathologic analysis of 27 cases. *Cancer* 1982;50:2438–2447.
- Bristow RE, Tomacruz RS, Armstrong DK, et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. *J Clin Oncol* 2002;20:1248–1259.
- Prat J; FIGO Committee on Gynecologic Oncology. Staging classification for cancer of the ovary, fallopian tube, and peritoneum. *Int J Gynaecol Obstet* 2014;124:1–5.
- Schumer ST, Cannistra SA. Granulosa cell tumor of the ovary. *J Clin Oncol* 2003;21:1180–1189.
- Young RC, Decker DG, Wharton JT, et al. Staging laparotomy in early ovarian cancer. *JAMA* 1983;250:3072–3076.
- Gershenson DM. Fertility-sparing surgery for malignancies in women. *J Natl Cancer Inst Monogr* 2005;34:43–47.
- Young RC, Walton LA, Ellenberg SS, et al. Adjuvant therapy in stage I and stage II epithelial ovarian cancer. Results of two prospective randomized trials. *N Engl J Med* 1990;322:1021–1027.
- Ahmed F, Wilshaw E, A'Hern R, et al. Natural history and prognosis of untreated stage I epithelial ovarian carcinoma. *J Clin Oncol* 1996;14:2968–2975.
- Ozols RF, Bundy BN, Greer BE, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. *J Clin Oncol* 2003;21:3194–3200.

62. McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. *N Engl J Med* 1996;334:1–6.
63. Hoskins WJ, Bundy BN, Thigpen JT, et al. The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study. *Gynecol Oncol* 1992;47:159–166.
64. Lavin PT, Knapp RC, Malkasian G, et al. CA 125 for the monitoring of ovarian carcinoma during primary therapy. *Obstet Gynecol* 1987;69:223–227.
65. Crawford SM, Paul J, Reed NS, et al. The prognostic significance of the CA 125 nadir in patients that achieve a CA 125 response. *Proc Am Soc Clin Oncol* 2004;23:448 (Abstr 5001).
66. Bolton KL, Chenevix-Trench G, Goh C, et al. Association between *brca1* and *brca2* mutations and survival in women with invasive epithelial ovarian cancer. *JAMA* 2012;307:382–390.
67. Van Der Zee AG, Hollema H, Suurmeijer AJ, et al. Value of P-glycoprotein, glutathione S-transferase pi, *c-erbB-2*, and *p53* as prognostic factors in ovarian carcinomas. *J Clin Oncol* 1995;13:70–78.
68. Spentzos D, Levine DA, Ramoni MF, et al. Gene expression signature with independent prognostic significance in epithelial ovarian cancer. *J Clin Oncol* 2004;22:4700–4710.
69. Spentzos D, Levine DA, Kolia S, et al. Unique gene expression profile based on pathologic response in epithelial ovarian cancer. *J Clin Oncol* 2005;23:7911–7918.
70. Trimbos JB, Parmar M, Vergote I, et al. International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy in Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. *J Natl Cancer Inst* 2003;95:105–112.
71. Young RC. Early-stage ovarian cancer: to treat or not to treat. *J Natl Cancer Inst* 2003;95:94–95.
72. Bell J, Brady M, Lage JM, et al. A randomized phase III trial of three versus six cycles of carboplatin and paclitaxel as adjuvant treatment in early stage ovarian epithelial carcinoma: a Gynecologic Oncology Group study. *Gynecol Oncol* 2003;88:156.
73. Chan JK, Tian C, Fleming GF, et al. The potential benefit of 6 vs. 3 cycles of chemotherapy in subsets of women with early-stage high-risk epithelial ovarian cancer: an exploratory analysis of a Gynecologic Oncology Group study. *Gynecol Oncol* 2010;116:301–306.
74. Markman M. Informing patients with cancer of “new findings” that may influence their willingness to participate in research studies. *Cancer* 2003;98:885–887.
75. Redman CW, Mould J, Warwick J, et al. The West Midlands epithelial ovarian cancer adjuvant therapy trial. *Clin Oncol (R Coll Radiol)* 1993;5:1–5.
76. Chiara S, Conte P, Franzoni P, et al. High-risk early-stage ovarian cancer. Randomized clinical trial comparing cisplatin plus cyclophosphamide versus whole abdominal radiotherapy. *Am J Clin Oncol* 1994;17:72–76.
77. Vergote IB, Vergote-De Vos LN, Abeler VM, et al. Randomized trial comparing cisplatin with radioactive phosphorus or whole-abdomen irradiation as adjuvant treatment of ovarian cancer. *Cancer* 1992;69:741–749.
78. Young RC, Brady MF, Nieberg RK, et al. Adjuvant treatment for early ovarian cancer: a randomized phase III trial of intraperitoneal ³²P or intravenous cyclophosphamide and cisplatin—a Gynecologic Oncology Group study. *J Clin Oncol* 2003;21:4350–4355.
79. Nagai Y, Inamine M, Hirakawa M, et al. Postoperative whole abdominal radiotherapy in clear cell adenocarcinoma of the ovary. *Gynecol Oncol* 2007;107:469–473.
80. Chang SJ, Bristow RE. Evolution of surgical treatment paradigms for advanced-stage ovarian cancer: redefining “optimal” residual disease. *Gynecol Oncol* 2012;125:483–492.
81. Van Der Burg ME, van Lent M, Buyse M, et al. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. *N Engl J Med* 1995;332:629–634.
82. Schwartz PE, Chambers JT, Makuch R. Neoadjuvant chemotherapy for advanced ovarian cancer. *Gynecol Oncol* 1994;53:33–37.
83. Vergote I, Trope CG, Amant F, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. *N Engl J Med* 2010;363:943–953.
84. Vergote I, du Bois A. Neoadjuvant chemotherapy in advanced ovarian cancer: on what do we agree and disagree? *Gynecol Oncol* 2013;128:6–11.
85. Kehoe S, Hook J, Nankivell M, et al. Chemotherapy or upfront surgery for newly diagnosed advanced ovarian cancer: results from the MRC CHORUS trial. *Proc Am Soc Clin Oncol* 2013;31:Abstr 5500.
86. Alberts DS, Green S, Hannigan EV, et al. Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer. *J Clin Oncol* 1992;10:706–717.
87. Thigpen JT, Blessing JA, Ball H, et al. Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study. *J Clin Oncol* 1994;12:1748–1753.
88. Piccart MJ, Bertelsen K, James K, et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. *J Natl Cancer Inst* 2000;92:699–708.
89. Muggia FM, Braly PS, Brady MF, et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study [see comment]. *J Clin Oncol* 2000;18:106–115.
90. International Collaborative Ovarian Neoplasm Group. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial. *Lancet* 2002;360:505–515.
91. Ozols RF, Markman M, Thigpen JT. ICON3 and chemotherapy for ovarian cancer. *Lancet* 2002;360:2086–2087; author reply 2088.
92. du Bois A, Luck HJ, Meier W, et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. *J Natl Cancer Inst* 2003;95:1320–1329.
93. Neijt JP, Engelholm SA, Tuxen MK, et al. Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. *J Clin Oncol* 2000;18:3084–3092.
94. Vasey PA, Jayson GC, Gordon A, et al. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. *J Natl Cancer Inst* 2004;96:1682–1691.
95. Hakes TB, Chalas E, Hoskins WJ, et al. Randomized prospective trial of 5 versus 10 cycles of cyclophosphamide, doxorubicin, and cisplatin in advanced ovarian carcinoma. *Gynecol Oncol* 1992;45:284–289.
96. Bertelsen K, Jakobsen A, Stroyer J, et al. A prospective randomized comparison of 6 and 12 cycles of cyclophosphamide, adriamycin, and cisplatin in advanced epithelial ovarian cancer: a Danish Ovarian Study Group trial (DACOVA). *Gynecol Oncol* 1993;49:30–36.
97. Bookman MA, Brady MF, McGuire WP, et al. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup. *J Clin Oncol* 2009;27:1419–1425.
98. Katsumata N, Yasuda M, Takahashi F, et al. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. *Lancet* 2009;374:1331–1338.
99. Rothenberg ML, Liu PY, Braly PS, et al. Combined intraperitoneal and intravenous chemotherapy for women with optimally debulked ovarian cancer: results from an intergroup phase II trial. *J Clin Oncol* 2003;21:1313–1319.
100. Alberts DS, Liu PY, Hannigan EV, et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. *N Engl J Med* 1996;335:1950–1955.
101. Markman M, Bundy BN, Alberts DS, et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. *J Clin Oncol* 2001;19:1001–1007.
102. Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. *N Engl J Med* 2006;354:34–43.
103. Walker JL, Armstrong DK, Huang HQ, et al. Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study. *Gynecol Oncol* 2006;100:27–32.
104. Cannistra SA. Intraperitoneal chemotherapy comes of age. *N Engl J Med* 2006;354:77–79.
105. Jaaback K, Johnson N. Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer. *Cochrane Database Syst Rev* 2006;(1):CD005340.
106. Gore M, du Bois A, Vergote I. Intraperitoneal chemotherapy in ovarian cancer remains experimental. *J Clin Oncol* 2006;24:4528–4530.
107. Ozols RF, Bookman MA, du Bois A, et al. Intraperitoneal cisplatin therapy in ovarian cancer: comparison with standard intravenous carboplatin and paclitaxel. *Gynecol Oncol* 2006;103:1–6.
108. Armstrong DK, Brady MF. Intraperitoneal therapy for ovarian cancer: a treatment ready for prime time. *J Clin Oncol* 2006;24:4531–4533.
109. Fujiwara K, Sakuragi N, Suzuki S, et al. First-line intraperitoneal carboplatin-based chemotherapy for 165 patients with epithelial ovarian carcinoma: results of long-term follow-up. *Gynecol Oncol* 2003;90:637–643.
110. Markman M, Walker JL, Armstrong DK, et al. Intraperitoneal chemotherapy of ovarian cancer: a review, with a focus on practical aspects of treatment. *J Clin Oncol* 2006;24:988–994.
111. Makhija S, Leitao M, Sabbatini P, et al. Complications associated with intraperitoneal chemotherapy catheters. *Gynecol Oncol* 2001;81:77–81.
112. Alberts DS, Markman M, Armstrong D, et al. Intraperitoneal therapy for stage III ovarian cancer: a therapy whose time has come! *J Clin Oncol* 2002;20:3944–3946.
113. Rose PG, Nerenstone S, Brady MF, et al. A randomized trial of secondary surgical cytoreduction in advanced ovarian carcinoma: a Gynecologic Oncology Group study. *N Engl J Med* 2004;351:2489.
114. Pickel H, Lahousen M, Petru E, et al. Consolidation radiotherapy after carboplatin-based chemotherapy in radically operated advanced ovarian cancer. *Gynecol Oncol* 1999;72:215–219.
115. Varia MA, Stehman FB, Bundy BN, et al. Intraperitoneal radioactive phosphorus (³²P) versus observation after negative second-look laparotomy for stage III ovarian carcinoma: a randomized trial of the Gynecologic Oncology Group. *J Clin Oncol* 2003;21:2849–2855.

116. Sørbe B. Consolidation treatment of advanced (FIGO stage III) ovarian carcinoma in complete surgical remission after induction chemotherapy: a randomized, controlled, clinical trial comparing whole abdominal radiotherapy, chemotherapy, and no further treatment. *Int J Gynecol Cancer* 2003;13:278–286.
117. Verheijen RH, Massuger LF, Benigno BB, et al. Phase III trial of intraperitoneal therapy with yttrium-90-labeled HMFG1 murine monoclonal antibody in patients with epithelial ovarian cancer after a surgically defined complete remission. *J Clin Oncol* 2006;24:571–578.
118. Swenerton KD, Santos JL, Gilks CB, et al. Histotype predicts the curative potential of radiotherapy: the example of ovarian cancers. *Ann Oncol* 2011;22:341–347.
119. Hoskins PJ, Le N, Gilks B, et al. Low-stage ovarian clear cell carcinoma: population-based outcomes in British Columbia, Canada with evidence for a survival benefit for irradiation. *J Clin Oncol* 2012;30:1656–1662.
120. Rochet N, Sterzing F, Jensen AD, et al. Intensity-modulated whole abdominal radiotherapy after surgery and carboplatin/taxane chemotherapy for advanced ovarian cancer: phase I study. *Int J Radiat Oncol Biol Phys* 2010;76:1382–1389.
121. Markman M, Liu PY, Wilczynski S, et al. Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial. *J Clin Oncol* 2003;21:2460–2465.
122. Pecorelli S, Favalli G, Cadducci A, et al. Phase III trial of observation versus six courses of paclitaxel in patients with advanced epithelial ovarian cancer in complete response after six courses of paclitaxel/platinum-based chemotherapy: final results of the After-6 Protocol. *J Clin Oncol* 2009;27:4642–4648.
123. Burger RA, Brady MF, Bookman MA, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. *N Engl J Med* 2011;365:2473–2483.
124. Perren TJ, Swart AM, Pfisterer J, et al. A phase 3 trial of bevacizumab in ovarian cancer. *N Engl J Med* 2011;365:2484–2496.
125. du Bois A, Floquet A, Kim JW, et al. Randomized, double-blind, phase III trial of pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: AGO-OVAR16. *Proc Am Soc Clin Oncol* 2013;31:Abstr LBA5503.
126. Ahlgren JD, Ellison NM, Gottlieb RJ, et al. Hormonal palliation of chemoresistant ovarian cancer: three consecutive phase II trials of the Mid-Atlantic Oncology Program. *J Clin Oncol* 1993;11:1957–1968.
127. Bowman A, Gabra H, Langdon SP, et al. CA 125 response is associated with estrogen receptor expression in a phase II trial of letrozole in ovarian cancer: identification of an endocrine-sensitive subgroup. *Clin Cancer Res* 2002;8:2233–2239.
128. Markman M, Rothman R, Hakes T, et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. *J Clin Oncol* 1991;9:389–393.
129. Parmar MK, Ledermann JA, Colombo N, et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. *Lancet* 2003;361:2099–2106.
130. Pfisterer J, Plante M, Vergote I, et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC CGC. *J Clin Oncol* 2006;24:4699–4707.
131. Pujade-Lauraine E, Wagner U, Avall-Lundqvist E, et al. Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. *J Clin Oncol* 2010;28:3323–3329.
132. Cannistra SA. Is there a “best” choice of second-line agent in the treatment of recurrent, potentially platinum-sensitive ovarian cancer? *J Clin Oncol* 2002;20:1158–1160.
133. Miller DS, Blessing JA, Krasner CN, et al. Phase II evaluation of pemetrexed in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: a study of the Gynecologic Oncology Group. *J Clin Oncol* 2009;27:2686–2691.
134. Markman M, Kennedy A, Webster K, et al. Phase 2 trial of liposomal doxorubicin (40 mg/m²) in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum. *Gynecol Oncol* 2000;78:369–372.
135. Sehouli J, Stengel D, Harter P, et al. Topotecan weekly versus conventional 5-day schedule in patients with platinum-resistant ovarian cancer: a randomized multicenter phase II trial of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group. *J Clin Oncol* 2011;29:242–248.
136. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. *N Engl J Med* 2004;350:2335–2342.
137. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. *N Engl J Med* 2006;355:2542–2550.
138. Miller KD. E2100: a phase III trial of paclitaxel versus paclitaxel/bevacizumab for metastatic breast cancer. *Clin Breast Cancer* 2003;3:421–422.
139. Burger RA, Sill MW, Monk BJ, et al. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. *J Clin Oncol* 2007;25:5165–5171.
140. Cannistra SA, Matulonis UA, Penson RT, et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. *J Clin Oncol* 2007;25:5180–5186.
141. Aghajanian C, Blank SV, Goff BA, et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. *J Clin Oncol* 2012;30:2039–2045.
142. Pujade-Lauraine E, Hilpert F, Weber B, et al. AURELIA: A randomized phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC). *J Clin Oncol* 2012;30:Abstr LBA5002.
143. Ten Bokkel Huinink WW, Sufliarsky J, Smit WM, et al. Safety and efficacy of patupilone in patients with advanced ovarian, primary fallopian, or primary peritoneal cancer: a phase I, open-label, dose-escalation study. *J Clin Oncol* 2009;27:3097–3103.
144. Karlan BY, Oza AM, Richardson GE, et al. Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer. *J Clin Oncol* 2012;30:362–371.
145. Matulonis UA, Berlin S, Ivy P, et al. Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer. *J Clin Oncol* 2009;27:5601–5606.
146. Fong PC, Boss DS, Yap TA, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. *N Engl J Med* 2009;361:123–134.
147. Gelmon KA, Tischkowitz M, Mackay H, et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. *Lancet Oncol* 2011;12:852–861.
148. Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. *N Engl J Med* 2012;366:1382–1392.
149. Gershenson DM, Sun CC, Bodurka D, et al. Recurrent low-grade serous ovarian cancer is relatively chemoresistant. *Gynecol Oncol* 2009;114:48–52.
150. Gershenson DM, Sun CC, Iyer RB, et al. Hormonal therapy for recurrent low-grade serous carcinoma of the ovary or peritoneum. *Gynecol Oncol* 2012;125:661–666.
151. Grisham RN, Sala E, Zhou Q, et al. Bevacizumab (Bev) for treatment of recurrent serous borderline (SB) or low-grade serous (LGS) ovarian cancer: A retrospective review of the Memorial Sloan-Kettering Cancer Center (MSKCC) experience. *J Clin Oncol* 2013;31:Abstr 5545.
152. Farley J, Brady WE, Vathipadiekal V, et al. Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study. *Lancet Oncol* 2013;14:134–140.
153. Crozter DR, Sun CC, Coleman RL, et al. Lack of effective systemic therapy for recurrent clear cell carcinoma of the ovary. *Gynecol Oncol* 2007;105:404–408.
154. Takano M, Sugiyama T, Yaegashi N, et al. Low response rate of second-line chemotherapy for recurrent or refractory clear cell carcinoma of the ovary: a retrospective Japan Clear Cell Carcinoma Study. *Int J Gynecol Cancer* 2008;18:937–942.
155. Berek JS, Hacker NF, Lagasse LD, et al. Survival of patients following secondary cytoreductive surgery in ovarian cancer. *Obstet Gynecol* 1983;61:189–193.
156. Firat S, Erickson B. Selective irradiation for the treatment of recurrent ovarian carcinoma involving the vagina or rectum. *Gynecol Oncol* 2001;80:213–220.
157. Albuquerque KV, Singla R, Potkul RK, et al. Impact of tumor volume-directed involved field radiation therapy integrated in the management of recurrent ovarian cancer. *Gynecol Oncol* 2005;96:701–704.
158. Brown AP, Jhingran A, Klopp AH, et al. Involved-field radiation therapy for locoregionally recurrent ovarian cancer. *Gynecol Oncol* 2013;130:300–305.
159. Trimble CL, Kosary C, Trimble EL. Long-term survival and patterns of care in women with ovarian tumors of low malignant potential. *Gynecol Oncol* 2002;86:34–37.
160. Bell DA, Scully RE. Ovarian serous borderline tumors with stromal microinvasion: a report of 21 cases. *Hum Pathol* 1990;21:397–403.
161. Lee KR, Scully RE. Mucinous tumors of the ovary: a clinicopathologic study of 196 borderline tumors (of intestinal type) and carcinomas, including an evaluation of 11 cases with “pseudomyxoma peritonei.” *Am J Surg Pathol* 2000;24:1447–1464.
162. Deavers MT, Gershenson DM, Tortolero-Luna G, et al. Micropapillary and cribriform patterns in ovarian serous tumors of low malignant potential: a study of 99 advanced stage cases. *Am J Surg Pathol* 2002;26:1129–1141.
163. Bell DA, Weinstock MA, Scully RE. Peritoneal implants of ovarian serous borderline tumors. Histologic features and prognosis. *Cancer* 1988;62:2212–2222.
164. Seidman JD, Kurman RJ. Ovarian serous borderline tumors: a critical review of the literature with emphasis on prognostic indicators. *Hum Pathol* 2000;31:539–557.
165. Trope C, Kaern J, Vergote IB, et al. Are borderline tumors of the ovary overtreated both surgically and systemically? A review of four prospective randomized trials including 253 patients with borderline tumors. *Gynecol Oncol* 1993;51:236–243.
166. Silva EG, Gershenson DM, Malpica A, et al. The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninvasive implants is time dependent. *Am J Surg Pathol* 2006;30:1367–1371.
167. Abu-Jawdeh GM, Jacobs TW, Niloff J, et al. Estrogen receptor expression is a common feature of ovarian borderline tumors. *Gynecol Oncol* 1996;60:301–307.

168. Billmire D, Vinocur C, Rescorla F, et al. Outcome and staging evaluation in malignant germ cell tumors of the ovary in children and adolescents: an intergroup study. *J Pediatr Surg* 2004;49:424-429.
169. Williams SD, Blessing JA, Hatch KD, et al. Chemotherapy of advanced dysgerminoma: trials of the Gynecologic Oncology Group. *J Clin Oncol* 1991;9:1950-1955.
170. Gershenson DM, Morris M, Cangir A, et al. Treatment of malignant germ cell tumors of the ovary with bleomycin, etoposide, and cisplatin. *J Clin Oncol* 1990;8:715-720.
171. Brewer M, Gershenson DM, Herzog CE, et al. Outcome and reproductive function after chemotherapy for ovarian dysgerminoma. *J Clin Oncol* 1999;17:2670-2675.
172. Williams SD, Kauderer J, Burnett AF, et al. Adjuvant therapy of completely resected dysgerminoma with carboplatin and etoposide: a trial of the Gynecologic Oncology Group. *Gynecol Oncol* 2004;95:496-499.
173. Williams S, Blessing JA, Liao SY, et al. Adjuvant therapy of ovarian germ cell tumors with cisplatin, etoposide, and bleomycin: a trial of the Gynecologic Oncology Group. *J Clin Oncol* 1994;12:701-706.
174. Gershenson DM, Miller AM, Champion VL, et al. Reproductive and sexual function after platinum-based chemotherapy in long-term ovarian germ cell tumor survivors: a Gynecologic Oncology Group study. *J Clin Oncol* 2007;25:2792-2797.
175. Sklar CA, Mertens AC, Mitby P, et al. Premature menopause in survivors of childhood cancer: a report from the childhood cancer survivor study. *J Natl Cancer Inst* 2006;98:890-896.
176. Dark CG, Bower M, Newlands ES, et al. Surveillance policy for stage I ovarian germ cell tumors. *J Clin Oncol* 1997;15:620-624.
177. Cushing B, Giller R, Ablin A, et al. Surgical resection alone is effective treatment for ovarian immature teratoma in children and adolescents: a report of the Pediatric Oncology Group and the Children's Cancer Group. *Am J Obstet Gynecol* 1999;181:353-358.
178. Gobel U, Schneider DT, Calaminus G, et al. Germ-cell tumors in childhood and adolescence. GPOH MAKEI and the MAHO study groups. *Ann Oncol* 2000;11:263-271.
179. Baranzelli MC, Bouffet E, Quintana E, et al. Non-seminomatous ovarian germ cell tumours in children. *Eur J Cancer* 2000;36:376-383.
180. Healy DL, Burger HG, Marnett P, et al. Elevated serum inhibin concentrations in postmenopausal women with ovarian tumors. *N Engl J Med* 1993;329:1539-1542.
181. Abu-Rustum N, Restivo A, Ivy J, et al. Retroperitoneal nodal metastasis in primary and recurrent granulosa cell tumors of the ovary. *Gynecol Oncol* 2006;103:31-34.
182. Brown J, Sood AK, Deavers MT, et al. Patterns of metastasis in sex cord-stromal tumors of the ovary: can routine staging lymphadenectomy be omitted? *Gynecol Oncol* 2009;113:86-90.
183. Homesley HD, Bundy BN, Hurteau JA, et al. Bleomycin, etoposide, and cisplatin combination therapy of ovarian granulosa cell tumors and other stromal malignancies: a Gynecologic Oncology Group study. *Gynecol Oncol* 1999;72:131-137.
184. Brown J, Shvartsman HS, Deavers MT, et al. The activity of taxanes in the treatment of sex cord-stromal ovarian tumors. *J Clin Oncol* 2004;22:3517-3523.
185. Tobacman JK, Greene MH, Tucker MA, et al. Intra-abdominal carcinomatosis after prophylactic oophorectomy in ovarian-cancer-prone families. *Lancet* 1982;2:795-797.
186. Muto MC, Welch WR, Mok SC, et al. Evidence for a multifocal origin of papillary serous carcinoma of the peritoneum. *Cancer Res* 1995;55:490-492.
187. Piver MS, Jishi MF, Tsukada Y, et al. Primary peritoneal carcinoma after prophylactic oophorectomy in women with a family history of ovarian cancer. A report of the Gilda Radner Familial Ovarian Cancer Registry. *Cancer* 1993;71:2751-2755.
188. Schiller HM, Silverberg SG. Staging and prognosis in primary carcinoma of the fallopian tube. *Cancer* 1971;28:389-395.